ACT NABILONE 1 MG
NABILONE : 1 MG · DIN 02393603 · TEVA CANADA LIMITED
Health Canada status: CANCELLED POST MARKET
What is ACT NABILONE?
ACT NABILONE 1 MG contains NABILONE : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02393603, held by TEVA CANADA LIMITED, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 11-Nov-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02393603 |
|---|---|
| Brand name | ACT NABILONE |
| Generic / active ingredient | NABILONE : 1 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 1 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA II) |
| ATC code | A04AD11 NABILONE |
| AHFS class | 56:22.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 11-Nov-2022 |
| Original market date | 2012-10-02 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code A04AD11 NABILONE. 9 of 17 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CESAMET | 0.25 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02312263 |
| CESAMET | 0.5 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02256193 |
| CESAMET | 1 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 00548375 |
| PMS-NABILONE | 0.25 MG | CAPSULE | PHARMASCIENCE INC | MARKETED | DIN 02380897 |
| PMS-NABILONE | 0.5 MG | CAPSULE | PHARMASCIENCE INC | MARKETED | DIN 02380900 |
| PMS-NABILONE | 1.0 MG | CAPSULE | PHARMASCIENCE INC | MARKETED | DIN 02380919 |
| TEVA-NABILONE | 0.25 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 02392925 |
| TEVA-NABILONE | 0.5 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 02384884 |
| TEVA-NABILONE | 1.0 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 02384892 |
| ACT NABILONE | 0.5 MG | CAPSULE | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02393581 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.